Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases

About this update from Jaguar Health, Inc.

Click here to register for eventTo access the replay of the June 10, 2026 presentation by Lisa Conte, Jaguar's founder, president & CEO, at the Emerging Growth Conference, click hereReminder: Two crofelemer presentations in pediatric intestinal failure patients with microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) to be conducted at June 24-27, 2026 Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) Meeting SAN FRANCISCO, CA / ACCESS Newswire / June 12, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Wednesday, June 24, 2026 at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com.Participation Instructions for Jaguar's Presentation at the Life Sciences Virtual Investor ForumWhen: Wednesday, June 24, 2026 at 1:00 PM EasternRegistration link for conference: Click HereReplay: A replay of the webcast will be available following the conclusion of the conference.About the Jaguar Health Family of CompaniesJaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome.For more information about:Jaguar Health, visit https://jaguar.healthNapo Pharmaceuticals, visit napopharma.comNapo Therapeutics, visit napotherapeutics.comForward-Looking StatementsCertain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the June 2026 conference listed above, and the expectation that two crofelemer-related presentations in pediatric intestinal failure patients with MVID and SBS-IF will be made at the 58th ESPGHAN Annual Meeting in June 2026. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate...

View stock analysis, news, and events for Jaguar Health, Inc.